Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales

Rhea-AI Filing Summary

Entrada Therapeutics Chief Financial Officer Kory James Wentworth reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 66,600 stock options and 44,600 restricted stock units under the 2021 Stock Option and Incentive Plan, both vesting in stages through March 1, 2030.

The filing also shows mandatory sell-to-cover transactions where the company automatically sold 5,712 shares at a weighted average price of $11.7564 on March 3, 2026 and 2,939 shares at $11.6579 on March 2, 2026 to cover minimum statutory tax withholding obligations, not discretionary trades by Wentworth. After these transactions, he directly owned 145,975 common shares and 66,600 options.

Insights

Equity compensation analyst

Routine equity grants and automatic tax sales for Entrada’s CFO.

Entrada Therapeutics granted its CFO, Kory James Wentworth, 66,600 stock options and 44,600 RSUs on March 1, 2026. Both awards vest gradually through March 1, 2030, tying a substantial portion of his compensation to long-term company performance.

Two Form 4 entries coded “F” disclose tax-withholding dispositions totaling 8,651 shares of common stock at weighted average prices of $11.7564 and $11.6579. Footnotes clarify these were mandatory sell-to-cover sales executed by the company to satisfy minimum statutory tax obligations, not discretionary market sales.

After these transactions, Wentworth directly held 145,975 common shares and 66,600 options. This pattern reflects standard executive equity compensation and tax handling rather than a directional view on Entrada Therapeutics (TRDA) stock. Subsequent filings may update his vested holdings as tranches vest over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		44,600(1)	A	$0(1)	154,626	D
Common Stock	03/02/2026		F		2,939(2)	D	$11.6579(3)	151,687	D
Common Stock	03/03/2026		F		5,712(2)	D	$11.7564(4)	145,975	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.93	03/01/2026		A		66,600		(5)	03/01/2036	Common Stock	66,600	$0	66,600	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

2. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Entrada Therapeutics (TRDA) CFO report on this Form 4?

Entrada Therapeutics CFO Kory James Wentworth reported equity awards and related tax sales. He received 66,600 stock options and 44,600 restricted stock units, plus two automatic tax-withholding share dispositions totaling 8,651 common shares sold at weighted average prices around $11.76 and $11.66.

How many stock options and RSUs did TRDA grant to its CFO in this filing?

The company granted its CFO 66,600 stock options and 44,600 restricted stock units. These awards were issued under Entrada’s 2021 Stock Option and Incentive Plan and are structured to vest over several years, aligning the executive’s potential compensation with long-term company performance.

Were the TRDA insider stock sales by the CFO discretionary market trades?

No, the reported sales were not discretionary trades. Footnotes state the company automatically sold shares under a mandatory sell-to-cover provision to meet minimum statutory tax withholding obligations, meaning the transactions were executed to cover taxes rather than reflect an active investment decision.

What were the prices and sizes of the TRDA tax-withholding share dispositions?

The filing shows 5,712 shares sold at a weighted average price of $11.7564 and 2,939 shares at $11.6579. Both transactions were coded as tax-withholding dispositions, executed to satisfy required tax obligations associated with the equity awards rather than open-market investment sales.

How do the CFO’s TRDA equity awards vest over time?

The RSUs vest 25% on March 1 of 2027, 2028, 2029, and 2030, contingent on continued service. The options vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments, fully vesting by March 1, 2030, if employment continues.

How many Entrada Therapeutics shares and options does the CFO hold after these transactions?

After the reported grants and tax-withholding dispositions, the CFO directly holds 145,975 shares of Entrada Therapeutics common stock and 66,600 stock options. These holdings reflect his updated ownership position following the March 2026 equity awards and associated mandatory sell-to-cover transactions.